The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA (“Ecstasy”) in Humans
Clinical Pharmacology & Therapeutics – June 15, 2011
Source: OpenAlex
Summary
Reboxetine significantly dampened the effects of ecstasy (MDMA) in a study involving 16 healthy participants. While MDMA raised plasma norepinephrine levels and heightened blood pressure, heart rate, and subjective feelings of stimulation, reboxetine effectively reduced these responses. Notably, even with increased MDMA and its active metabolite concentrations, reboxetine's influence was evident. These findings underscore the importance of norepinephrine transporter activity in mediating the stimulant effects of MDMA, highlighting potential implications for pharmacology and forensic toxicology in understanding drug interactions.
Abstract
This study assessed the pharmacodynamic and pharmacokinetic effects of the interaction between the selective norepinephrine (NE) transporter inhibitor reboxetine and 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in 16 healthy subjects. The study used a double-blind, placebo-controlled crossover design. Reboxetine reduced the effects of MDMA including elevations in plasma levels of NE, increases in blood pressure and heart rate, subjective drug high, stimulation, and emotional excitation. These effects were evident despite an increase in the concentrations of MDMA and its active metabolite 3,4-methylenedioxyamphetamine (MDA) in plasma. The results demonstrate that transporter-mediated NE release has a critical role in the cardiovascular and stimulant-like effects of MDMA in humans.